Organisation: European Medicines Agency

Members of INTA’s Brand Restrictions Committee chart the impact of brand restrictions on multiple product sectors, and how the association is engaging with policymakers on the issue.

16 November 2023

The court provided much needed guidance on how to reconcile trademark rights and the free movement of goods in relation to the parallel import of generic medicines.

02 December 2022

Rachel Cockburn Buhl, head of brand IP at biopharmaceutical group Ferring, reveals how she has expanded the function’s internal expertise to provide wider business support while having a positive budget impact.

22 June 2022

WTR spoke to Gilead's Gretchen Stroud about the fight against fake drugs being sold on social media, the trademark challenges that arise when drugs go off-patent, and much more.

24 October 2018

In <i>PI Pharma v Novartis</i>, the Brussels Court of Appeal has expressed its views on the notification obligation of parallel importers of repackaged pharmaceuticals. It ruled that PI Pharma had not properly notified Novartis, the holder of the VENORUTON mark, when it provided a blister and a two-dimensional mock-up of the outer packaging, rather than an actual sample, of the repackaged pharmaceutical as it would be presented on sale.

04 March 2013